Abstract:Background: MicroRNA-106b (miR-106b) is thought to be an oncogenic microRNA that promotes tumor growth and metastasis. The potential predictive value of miR-106b was studied in colonic cancer patients. Methods: The expression of miR-106b was examined in 180 colonic cancer cases using in situ hybridization (ISH) technique and was evaluated semi-quantitatively by examining the staining index. The Correlation of miR-106b expression and clinic-pathological features was analyzed by Spearman Rank Correlation. Wilcoxon signed rank test was used for assessing the expression difference of miRNA-106b between colonic cancerous and para-cancerous ones, and their effects on patient survival were analyzed by a log-rank test and the Kaplan-Meier method. Results: MiR-106b was higher expressed in para-cancerous tissues, compared with colonic cancerous ones (P < 0.001). A positive correlation of miR-106b levels between colonic and para-cancerous tissues was also observed (CC = 0.523, P < 0.001). Furthermore, the expression of miR-106b was not significantly correlated with clinic-pathological parameters, including gender, age, histological grade, tumor size, pT stage, pN stage, pM stage and pTNM stage of the patients. Histological grade was positively correlated with pT stage (P = 0.011), pN stage (P = 0.036) and pTNM stage (P = 0.009). Patients expressing high levels of miR-106b both in colonic cancer tissues and para-cancerous ones have a relatively longer survival time but the difference is not statistically significant (P = 0.16). Conclusions: The expression difference of miR-106b levels between colonic tissues and para-cancerous tissues is statistically significant, but the miR-106b levels were not quite correlated with clinic-pathological characteristics and overall survival times of patients with colonic cancer. Lower levels of miR-106b may be connected with neoplastic effects due to interference with TGF-beta signaling, providing evidence that down-regulation of miR-106b might also play an important role in the progression of the disease. The study results are consistent with the literature and support the notion that miR-106b is an oncogenic microRNA.

Analysis of Hsa-Mir-30a-5p Expression in Human Gliomas

A Predicted Mir-27A-mediated Network Identifies a Signature of Glioma.

Mir-182 As a Prognostic Marker for Glioma Progression and Patient Survival

A Study on the Expression of Mir-106B ∼ 25 Cluster in Human Glioma

miR-19a and miR-19b Overexpression in Gliomas

Upregulation of Mir-183 Expression and Its Clinical Significance in Human Brain Glioma

The Use of Hsa-Mir-21, Hsa-Mir-181b and Hsa-Mir-106a As Prognostic Indicators of Astrocytoma.

miR-30c plays diagnostic and prognostic roles and mediates epithelial–mesenchymal transition (EMT) and proliferation of gliomas by affecting Notch1

Identification of Differentially Expressed Micrornas and the Potential of Microrna-455-3p As a Novel Prognostic Biomarker in Glioma

Preliminary study on the nuRNA expression profiles in several glioma cell lines

Upregulation of hsa-miR-196a-5p is associated with MIR196A2 methylation and affects the malignant biological behaviors of glioma

In Situ Hybridization Analysis of the Expression of Mir-106B in Colonic Cancer.

Expression of Microrna-184 in Glioma

The Relationship between Expression of the miR-181 Family and Malignancy of Human Glioma

Decreased Expression of Microrna-107 Predicts Poorer Prognosis in Glioma

Correlation of microRNA-10b upregulation and poor prognosis in human gliomas

Downregulation of Mir-154 in Human Glioma and Its Clinicopathological and Prognostic Significance

Serum Microrna-376 Family As Diagnostic and Prognostic Markers in Human Gliomas.

Inhibitory Effect of Knocking Down Mir-30A-5p on the Growth of U251 Glioma Cells

Inhibitory Effect of Antisense Mir-30A-5p on Glioma Cell Growth in Vivo

miR-181b Expression in Human Gliomas and Its Clinical Significance